Full Name
ROSS ANDREW SOO
Variants
Ross, S.
Soo, R.
Soo, R.-A.
Soo, R.A.
Soo, Ross
 
 
 
Email
csiras@nus.edu.sg
 

Publications

Results 1-20 of 49 (Search time: 0.01 seconds).

Issue DateTitleAuthor(s)
1Apr-2012A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancerNg, K.P.; Hillmer, A.M.; Chuah, C.T.H.; Juan, W.C.; Ko, T.K. ; Teo, A.S.M.; Ariyaratne, P.N.; Takahashi, N.; Sawada, K.; Fei, Y.; Soh, S.; Lee, W.H.; Huang, J.W.J.; Allen Jr., J.C.; Woo, X.Y.; Nagarajan, N.; Kumar, V.; Thalamuthu, A.; Poh, W.T.; Ang, A.L.; Mya, H.T.; How, G.F.; Yang, L.Y.; Koh, L.P.; Chowbay, B.; Chang, C.-T.; Nadarajan, V.S.; Chng, W.J.; Than, H.; Lim, L.C.; Goh, Y.T.; Zhang, S.; Poh, D.; Tan, P. ; Seet, J.-E.; Ang, M.-K.; Chau, N.-M.; Ng, Q.-S.; Tan, D.S.W.; Soda, M.; Isobe, K.; Nöthen, M.M.; Wong, T.Y. ; Shahab, A.; Ruan, X.; Cacheux-Rataboul, V.; Sung, W.-K.; Tan, E.H.; Yatabe, Y.; Mano, H.; Soo, R.A. ; Chin, T.M. ; Lim, W.-T.; Ruan, Y. ; Ong, S.T.
2Nov-2011A comparative study of dynamic contrast-enhanced MRI parameters as biomarkers for anti-angiogenic drug therapyKoh, T.S.; Thng, C.H.; Hartono, S.; Tai, B.C. ; Rumpel, H.; Ong, A.B.; Sukri, N.; Soo, R.A. ; Wong, C.I.; Low, A.S.C.; Humerickhouse, R.A.; Goh, B.C.
3Apr-2008A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cellsMa, B.; Goh, B.C.; Tan, E.H.; Lam, K.C.; Soo, R. ; Leong, S.S.; Wang, L.Z. ; Mo, F.; Chan, A.T.C.; Zee, B.; Mok, T.
4Jul-2006A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancerSoo, R.A. ; Wang, L.Z. ; Tham, L.S.; Yong, W.P. ; Boyer, M.; Lim, H.L.; Lee, H.S.; Millward, M.; Liang, S.; Beale, P.; Lee, S.C. ; Goh, B.C.
5Jul-2008A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancersYong, W.-P. ; Wang, L.-Z. ; Tham, L.-S.; Wong, C.-I.; Lee, S.-C. ; Soo, R. ; Sukri, N.; Lee, H.-S.; Goh, B.-C.
6Oct-2012Activation of IL-6R/JAK1/STAT3 signaling induces De Novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutationKim, S.M.; Kwon, O.-J.; Hong, Y.K.; Kim, J.H.; Solca, F.; Ha, S.-J.; Soo, R.A. ; Christensen, J.G.; Lee, J.H.; Cho, B.C.
7Oct-2013Can population differences in chemotherapy outcomes be inferred from differences in pharmacogenetic frequenciesLoh, M. ; Chua, D.; Yao, Y.; Soo, R.A. ; Garrett, K.; Zeps, N.; Platell, C.; Minamoto, T.; Kawakami, K.; Iacopetta, B.; Soong, R. 
8May-2009Clinical pharmacology and pharmacogenetics of gemcitabineWong, A.; Soo, R.A. ; Yong, W.-P. ; Innocenti, F.
9Apr-2012Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapySoo, R.A. ; Kawaguchi, T.; Loh, M. ; Ou, S.-H.I.; Shieh, M.P.; Cho, B.-C.; Mok, T.S.; Soong, R. 
101-Feb-2012Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangementKim, H.R.; Shim, H.S.; Chung, J.-H.; Lee, Y.J.; Hong, Y.K.; Rha, S.Y.; Kim, S.H.; Ha, S.-J.; Kim, S.K.; Chung, K.Y.; Soo, R. ; Kim, J.H.; Cho, B.C.
11Dec-2008Does saturable formation of gemcitabine triphosphate occur in patients?Tham, L.-S.; Wang, L.-Z. ; Soo, R.A. ; Lee, H.-S.; Lee, S.-C. ; Goh, B.-C.; Holford, N.H.G.
12Jun-2011Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: Results of a meta-analysis of randomized controlled trialsSoo, R.A. ; Loh, M. ; Mok, T.S.; Ou, S.-H.I.; Cho, B.-C.; Yeo, W.-L. ; Tenen, D.G.; Soong, R. 
13Apr-2008Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancerWong, A.S.; Soong, R. ; Seah, S.B.-K.; Lim, S.-W. ; Chuah, K.-L.; Nga, M.-E.; Chin, T.-M. ; Soo, R.A. 
1420-Feb-2013Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancerKim, H.R.; Kim, D.J.; Kang, D.R.; Lee, J.G.; Lim, S.M.; Lee, C.Y.; Rha, S.Y.; Bae, M.K.; Lee, Y.J.; Kim, S.H.; Ha, S.-J.; Soo, R.A. ; Chung, K.Y.; Kim, J.H.; Lee, J.H.; Shim, H.S.; Cho, B.C.
15Nov-2009First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009Soo, R.A. ; Anderson, B.O.; Cho, B.C.; Yang, C.-H.; Liao, M.; Lim, W.-T.; Goldstraw, P.; Mok, T.S.
1620-Jan-2012Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesisZhang, W.C.; Ng, S.-C.; Yang, H.; Rai, A.; Umashankar, S.; Ma, S.; Soh, B.S.; Sun, L.L.; Tai, B.C. ; Nga, M.E.; Bhakoo, K.K.; Jayapal, S.R.; Nichane, M.; Yu, Q.; Ahmed, D.A.; Tan, C.; Sing, W.P.; Tam, J.; Thirugananam, A.; Noghabi, M.S.; Pang, Y.H.; Ang, H.S.; Robson, P.; Kaldis, P.; Soo, R.A. ; Swarup, S. ; Lim, E.H.; Lim, B.
17May-2011How many adenocarcinoma lung cancers come from bronchioloalveolar carcinoma?Wong, A.S.; Seto, K.-Y.; Ang, B.; Wong, E.; Chin, T.-M. ; Nga, M.-E.; Soo, R.A. 
187-Oct-2011INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancerWu, Y.-L.; Park, K.; Soo, R.A. ; Sun, Y.; Tyroller, K.; Wages, D.; Ely, G.; Yang, J.C.-H..; Mok, T.
192013Isolation and retrieval of circulating tumor cells using centrifugal forcesHou, H.W.; Warkiani, M.E.; Khoo, B.L.; Li, Z.R.; Soo, R.A. ; Tan, D.S.-W.; Lim, W.-T.; Han, J.; Bhagat, A.A.S.; Lim, C.T. 
20Apr-2006Ketoconazole renders poor CYP3A phenotype status with midazolam as probe drugTham, L.-S.; Lee, H.-S.; Wang, L. ; Yong, W.-P. ; Fan, L.; Ong, A.-B.; Sukri, N.; Soo, R. ; Lee, S.-C. ; Goh, B.-C.